title: Acute injection of ASP in the third ventricle inhibits food intake and locomotor activity in rats.
abstract: Acylation-stimulating protein (ASP; also known as C3adesArg) stimulates triglyceride synthesis and glucose transport via interaction with its receptor C5L2, which is expressed peripherally (adipose tissue, muscle) and centrally. Previous studies have shown that ASP-deficient mice (C3KO) and C5L2-deficient mice (C5L2KO) are hyperphagic (59 to 229% increase, P < 0.0001), which is counterbalanced by increased energy expenditure measured as oxygen consumption (Vo(2)) and a lower RQ. The aim of the present study was to evaluate ASP's effect on food intake, energy expenditure, and neuropeptide expression. Male rats were surgically implanted with intracerebroventricular (icv) cannulas directed toward the third ventricle. After a 5-h fast, rats were injected, and food intake was assessed at 0.5, 1, 2, 4, 16, 24, and 48 h, with a 5- to 7-day washout period between each injection. Acute icv injections of ASP (0.3-1,065 pmol) had a time-dependent effect on decreasing food intake by 20 to 57% (P < 0.05). Decreases were detected by 30 min (maximum 57%, P < 0.01) and at the highest dose effects extended to 48 h (19%, P < 0.05, 24- to 48-h period). Daily body weight gain was decreased by 131% over the first 24 h and 29% over the second 24 h (P < 0.05). A conditioned taste aversion test indicated that there was no malaise. Furthermore, acute ASP injection affected energy substrate usage, demonstrated by decreased Vo(2) and RQ (P < 0.05; implicating greater fatty acid usage), with a 49% decrease in total activity over 24 h (P < 0.05). ASP administration also increased anorexic neuropeptide POMC expression (44%) in the arcuate nucleus, with no change in NPY. Altogether ASP may have central in addition to peripheral effects.
authors.affiliation: Centre de Recherche Institut Universitaire de Cardiologie et Pneumologie de Québec, Sainte-Foy, Quebec, Canada.
authors.forename: Christian
authors.initials: C
authors.lastname: Roy
authors.forename: Marie-Claude
authors.initials: MC
authors.lastname: Roy
authors.forename: Danny
authors.initials: D
authors.lastname: Gauvreau
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Poulin
authors.forename: Fun-Qun
authors.initials: FQ
authors.lastname: Tom
authors.forename: Elena
authors.initials: E
authors.lastname: Timofeeva
authors.forename: Denis
authors.initials: D
authors.lastname: Richard
authors.forename: Katherine
authors.initials: K
authors.lastname: Cianflone
mesh_terms: D000818:Animals; D000855:Anorexia / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism; D002555:Cerebrospinal Fluid / Q000502:physiology; D003176:Complement C3; D015536:Down-Regulation / Q000187:drug effects; D004435:Eating / Q000187:drug effects*; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D007276:Injections, Intraventricular; D036341:Intercellular Signaling Peptides and Proteins / Q000008:administration & dosage* / Q000009:adverse effects / Q000494:pharmacology*; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D010101:Oxygen Consumption / Q000187:drug effects / Q000502:physiology; D011333:Pro-Opiomelanocortin / Q000235:genetics / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000494:pharmacology; D013997:Time Factors
chemical_list: C038245:C3 protein, human; D003176:Complement C3; D036341:Intercellular Signaling Peptides and Proteins; D011994:Recombinant Proteins; D011333:Pro-Opiomelanocortin